Share

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UP-LIFT)

Project objectives

PFS, QoL.

Start and end date

2022 - Ongoing

Project Manager

Prof. Angioli Roberto - Coordinator

Coordinating institution of the project

UCBM
QUICK LINKS
magnifiercrossmenuchevron-downchevron-leftchevron-right